ATRX and central nervous system cancer: This approach is highlighted by the WHO classification of gliomas updated in 2016 [4] which stated that the key prognostic determinants in glioma are genomic and proteomic, rather than histopathological, analyses including mutations in isocitrate dehydrogenase (IDH), alpha-thalassemia/mental retardation syndrome X-linked (ATRX), tumour protein p53 and O6‐alkylguanine DNA‐alkyltransferase MGMT genes and 1p/19q co-deletion which have already been shown to influence glioma malignancy and treatment response [4, 23].